COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)

Protocol No
KARTOS-KRT-232-117-CML
Principal Investigator
Ehab Atallah
Phase
I/II
Summary
In this study, we want to find out more about the side effects (problems and symptoms) of an investigational drug for Chronic Myeloid Leukemia, KRT-232, and what doses of KRT-232 are safe for people to take in addition to the current approved Tyrosine Kinase Inhibitor (TKI) treatment of nilotinib or dasatinib. Everyone in this study will receive KRT-232.
Description
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL